Abstract

The present disclosure relates to RNA molecules encoding a Neisseria meningitidis polypeptide. The present disclosure further relates to compositions comprising the RNA molecules formulated in a lipid nanoparticle (RNA-LNP). The present disclosure further relates to the use of the RNA molecules, RNA-LNPs and compositions for the treatment and/or prevention of meningococcal disease.

IPC Classes  ?

• A61K 39/095 - Neisseria
• A61P 31/04 - Antibacterial agents

Abstract

Compounds are provided having the following structure (I) or a pharmaceutically acceptable salt, N-oxide, tautomer or stereoisomer thereof, wherein R1, R2, R3, R4, G1, G2and G3 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a nucleic acid, compositions comprising the compounds and methods for their use and preparation are also provided.

IPC Classes  ?

• C07C 219/24 - Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups or amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
• A61K 9/51 - Nanocapsules
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant

Abstract

Compounds are provided having the following structure: (I) or a pharmaceutically acceptable salt, N-oxide, tautomer or stereoisomer thereof, wherein R1,G1, L1, L2, R2, R3, a, and b are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a nucleic acid, compositions comprising the compounds and methods for their use and preparation are also provided.

IPC Classes  ?

• C07D 211/22 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulfur atoms by oxygen atoms
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy

Abstract

The present disclosure relates to RNA molecules encoding a respiratory syncytial virus (RSV) polypeptide. The present disclosure further relates to compositions comprising the RNA molecules formulated in a lipid nanoparticle (RNA-LNP). The present disclosure further relates to the use of the RNA molecules, RNA-LNPs and compositions for the treatment and/or prevention of RSV infection-induced acute respiratory tract illness, including pneumonia and bronchitis.

IPC Classes  ?

• C12N 15/67 - General methods for enhancing the expression
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• A61K 39/12 - Viral antigens

Abstract

The invention relates to compounds of Formula (I): (I), and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds the present invention may be useful in the treatment, prevention, suppression and amelioration diseases, disorders, and conditions such as cancers.

IPC Classes  ?

• A61P 35/00 - Antineoplastic agents
• A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
• A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
• A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
• A61K 31/443 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
• C07D 207/16 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• C07D 209/54 - Spiro-condensed
• C07D 211/60 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• C07D 221/20 - Spiro-condensed ring systems
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Abstract

Provided are a combination therapy comprising inavolisib, palbociclib and fulvestrant and methods of treating PIC3CA-mutant, hormone receptor positive (HR+) and HER2 negative (HER2-) locally advanced or metastatic breast cancer comprising administering a therapeutically effective amount of inavolisib, palbociclib and fulvestrant. The combination therapy produces a statistically significant and clinically meaningful improvement to the patient as compared to administering palbociclib and fulvestrant alone to a comparable patient.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
• A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
• A61P 35/00 - Antineoplastic agents

Abstract

The present disclosure relates to benzodiazepine compounds and pharmaceutically acceptable salts thereof to their use in medicine; to pharmaceutical compositions containing them; to processes for their preparation; and to intermediates used in such processes. The benzodiazepine compounds may be useful in the treatment, prevention, suppression and amelioration of RSV infections.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• A61P 31/14 - Antivirals for RNA viruses
• A61K 31/5513 - 1,4-Benzodiazepines, e.g. diazepam

Abstract

Provided herein are methods of treating and/or managing multiple myeloma, which comprise administering to a patient 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione ("Compound A"), or an enantiomer or a mixture of enantiomers, a tautomer, an isotopolog, a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, in combination with a bispecific antibody comprising a first binding part binding to B cell maturation antigen (BCMA) and a second binding part binding to cluster of differentiation 3 (CD3).

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 35/00 - Antineoplastic agents
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more influenza antigens, such as hemagglutinin antigens.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses

Abstract

This disclosure relates novel methods to prepare 1,5-anhydro-3-({5-chloro-4-[4- fluoro-2-(2-hydroxypropan-2-yl)-1-(propan-2-yl)-1H-benzimidazol-6-yl]pyrimidin-2- yl}amino)-2,3-dideoxy-D-threo-pentitol, and hydrates and stereoisomers thereof, as well as intermediates, including solid forms of the intermediates, useful for the preparation of such compounds and the synthesis of said intermediates.

IPC Classes  ?

• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 309/14 - Nitrogen atoms not forming part of a nitro radical
• C07F 5/04 - Esters of boric acids

Abstract

Disclosed herein are antibodies, agonist peptides, and dual agonist peptides. Further disclosed herein are antibody conjugates comprising the antibodies, agonist peptides, and/or dual agonist peptides disclosed herein. In some embodiments, the antibodies or antibody conjugates of the invention may be used to treat metabolic diseases.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum

Abstract

Described herein are 3-phenylbenzo[b]thiophene carboxylic acid and 3-phenylbenzo[b]furan carboxylic acid derivatives and uses thereof in therapy. A crystalline form of 6-fluoro-3-(2,4,5-trifluoro-3- methoxyphenyl)-1-benzothiophene-2-carboxylic acid is also disclosed. The compounds disclosed herein can be used as a branched-chain alpha keto acid dehydrogenase kinase inhibitor or a degrader to treat conditions, for example, diabetes, kidney disease, nonalcoholic steatohepatitis, and heart failure.

IPC Classes  ?

• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 35/00 - Antineoplastic agents
• C07D 333/70 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings

Abstract

Provided herein are antibodies (including antigen-binding fragments thereof) that specifically bind to MIGIS-alpha, including for example without limitation, bispecific MIGIS-alpha/CD3 antibodies, other related antibodies, related nucleic acids, uses, and associated methods thereof. The disclosure also provides processes for making, preparing, and producing antibodies disclosed herein, including antibodies that bind to one or both of MIGIS-alpha and CD3.

IPC Classes  ?

• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07K 16/42 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against immunoglobulins (anti-idiotypic antibodies)
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The invention relates to an oral controlled-release matrix formulations of danuglipron or a pharmaceutically acceptable salt thereof (e.g. tris salt of danuglipron) and process of making such formulations. The present invention further relates to tablets having such formulations and methods of using these formulations and/or tablets once daily for weight management control or for treating, e.g., T2DM, obesity, or overweight.

IPC Classes  ?

• A61K 9/20 - Pills, lozenges or tablets
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

The invention relates to compounds and immunoconjugates of Formula (IV) and pharmaceutically acceptable salts thereof, to the use of the compounds and immunoconjugates in medicine, to compositions containing the compounds and immunoconjugates; to processes for preparing the compounds and immunoconjugates, and to intermediates used in such processes. The compounds and immunoconjugates of the invention may be useful in the treatment of cancer.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• A61P 35/00 - Antineoplastic agents
• A61K 31/4353 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems

Abstract

The present invention relates an in-vitro method of forming multi-specific antibodies from first and second homodimer antibodies. The invention also relates to multi-specific antibodies produced from the method.

IPC Classes  ?

• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• C07K 16/46 - Hybrid immunoglobulins

Abstract

The application relates to nitrogen-linked benzisoxazole sulfonamide derivatives or pharmaceutically acceptable salts thereof which act as Lysine Acetyl Transferase (KAT) inhibitors useful in the treatment of abnormal cell growth, such as cancer, in patients. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth, such as cancer, in patients.

IPC Classes  ?

• A61P 35/00 - Antineoplastic agents
• C07D 261/20 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 471/04 - Ortho-condensed systems
• C07D 487/04 - Ortho-condensed systems
• C07D 498/04 - Ortho-condensed systems
• A61K 31/423 - Oxazoles condensed with carbocyclic rings

Abstract

The invention relates to lipid nanoparticles, immunogenic compositions and methods for use thereof.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
• A61K 9/51 - Nanocapsules
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants

Abstract

The invention relates to a method for filling containers in sterile conditions with a pharmaceutical product, comprising the steps of: - supplying a plurality of sterile empty containers (1) into an infeed station, wherein each empty container comprises a cap assembly; - sequentially transferring the empty containers to a filling enclosure (55); - performing a filling cycle, comprising the sequential steps of a) introducing a group of empty container(s) into the filling enclosure (55); b) at least partially closing the filling enclosure (55); c) sterilizing an external surface of the empty container(s) by application of radiation; d) introducing a filling needle (75) through the fixed part (13) of the cap assembly and dispensing a pre-defined amount of pharmaceutical product into each container (1); e) opening the filling enclosure (55) and extracting the group of filled container(s); - repeating a filling cycle with a subsequent group of empty container(s). The invention is also directed to a related filling system.

IPC Classes  ?

• B65B 3/00 - Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans or jars
• B65B 3/04 - Methods of, or means for, filling the material into the containers or receptacles
• B65B 7/28 - Closing semi-rigid or rigid containers or receptacles not deformed by, or not taking-up shape of, contents, e.g. boxes or cartons by applying separate preformed closures, e.g. lids, covers
• B65B 31/02 - Filling, closing, or filling and closing, containers in chambers maintained under vacuum or superatmospheric pressure or containing a special atmosphere, e.g. of inert gas
• B65B 39/12 - Nozzles, funnels or guides for introducing articles or materials into containers or wrappers movable towards, or away from, container or wrapper during filling or depositing
• B65B 43/42 - Feeding or positioning bags, boxes, or cartons in the distended, opened, or set-up stateFeeding preformed rigid containers, e.g. tins, capsules, glass tubes, glasses, to the packaging positionLocating containers or receptacles at the filling positionSupporting containers or receptacles during the filling operation
• B65B 43/59 - Means for supporting containers or receptacles during the filling operation vertically movable
• B65B 55/02 - Sterilising, e.g. of complete packages
• B65B 55/08 - Sterilising wrappers or receptacles prior to, or during, packaging by irradiation

Abstract

This invention provides methods for producing homogeneous adjuvant formulations comprising a liposome bilayer comprising (a) monophosphoryl lipid A (MPLA), (b) a saponin, and (c) a liposome composition comprising (i) at least one phospholipid selected from 5 phosphatidylcholine (PC) and/or phosphatidylglycerol (PG), wherein the phospholipid is selected from the group consisting of dimyristoyl phosphatidylcholine (DMPC), dipalmitoyl phosphatidylcholine (DPPC), distearyl phosphatidylcholine (DSPC), dimyristoyl phosphatidylglycerol (DMPG), dipalmitoyl phosphatidylglycerol (DPPG), distearyl phosphatidylglycerol (DSPG), and a combination thereof, and (ii) cholesterol wherein the mole 0 percent concentration of the cholesterol in the liposome composition is greater than 50% (mol/mol), and further provides the homogeneous adjuvant formulations produced from said methods.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 39/12 - Viral antigens
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

Streptococcus pneumoniaeStreptococcus pneumoniae. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said novel immunogenic compositions.

IPC Classes  ?

• A61K 39/09 - Streptococcus
• A61P 31/04 - Antibacterial agents

Abstract

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more influenza antigens, such as hemagglutinin antigens.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses

Abstract

Described are methods, systems, and compositions for continuous production of RNA molecules in a continuous-flow in vitro transcription reaction with immobilized non- consumables. Also described are methods and systems for continuous production of RNA drug substance and RNA drug product from raw materials within an integrated, end-to-end, continuous-flow manufacturing skid.

Abstract

The invention relates to compounds of Formula (I) (I) wherein Y1a, Y1b, Y2a, Y2b, Y2c, Y2d, Y2e, Y2f, Y2g, Y2hand Y2i are as defined herein and to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of Formula (I) may be useful in the treatment of coronavirus infections and coronavirus infection related disorders.

IPC Classes  ?

• A61P 31/12 - Antivirals
• C07D 207/267 - 2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atom

Abstract

The invention relates to a method for treating cancer comprising administering to a subject Compound A having a structure of: or a pharmaceutically acceptable salt thereof, wherein treatment of the Compound A, or the pharmaceutically acceptable salt thereof, is not to be administered with concomitant administration of a CYP3A inducer, and particularly, a CYP3A4 inducer.

IPC Classes  ?

• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 35/00 - Antineoplastic agents
• A61P 35/04 - Antineoplastic agents specific for metastasis

Abstract

The present disclosure provides compounds that are inducers of KLF2 and pharmaceutical compositions comprising the same. The present disclosure further provides method of treating an inflammatory disease or endothelial dysfunction comprising administering a therapeutically effective amount of the compounds disclosed herein.

IPC Classes  ?

• C07D 498/04 - Ortho-condensed systems
• C07B 59/00 - Introduction of isotopes of elements into organic compounds
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine

Abstract

The invention relates to an injection device comprising a housing (3), an actuation member (20), an injection drive mechanism (25) for driving a plunger (9) within a medicament container (5), the injection drive mechanism including o a plunger rod (31) axially movable for driving the plunger (9); and o an injection compression spring (34) having coils (36) and arranged for biasing the plunger rod (31) to its distal position, the compression spring moving the plunger rod (31) distally as it axially expands. The device (1) further includes a clicking member (38) for generating an audible signal as the injection progresses, said clicking member comprising, fixed within the housing (3), a flexible blade bearing on the coils (36) of the compression spring (34) to produce the audible signal as the compression spring expands.

IPC Classes  ?

• A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
• A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles

Abstract

The present disclosure describes therapies and uses including an anti-BCMA / anti-CD3 bispecific antibody for the treatment of cancer and/or cancer-associated diseases.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents

Abstract

The present disclosure provides isolated immunogenic polypeptides comprising variant coronavirus spike proteins that are variants of a native coronavirus spike protein or fragment thereof. The present disclosure also provides compositions comprising the isolated immunogenic polypeptides and methods of making and using such compositions.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses

Abstract

Compounds are provided having the following structure: or a pharmaceutically acceptable salt, or stereoisomer thereof, wherein R1, R2, R3, R4, R5, Y, m, n, w and x are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a payload, compositions comprising the compounds and methods for their use and preparation are also provided.

IPC Classes  ?

• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/12 - Viral antigens
• A61K 47/58 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

The invention relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, L, X, Y and p are as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of Formula (I) may modulate the activity of antigens of interest and may be useful in inducing or enhancing an immune response against diseases, disorders and conditions mediated by antigens of interest.

IPC Classes  ?

• A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61P 37/04 - Immunostimulants

Abstract

Disclosed herein is a crystalline form of zavegepant, wherein the crystalline form is a crystalline monohydrochloride acetone solvate. Also disclosed herein is an amorphous form of the hydrochloride salt of zavegepant. Methods of making these solid forms as well as pharmaceutical compositions comprising the same are also disclosed.

IPC Classes  ?

• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/06 - Antimigraine agents
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin

Abstract

This invention relates to high drug loading formulations comprising solid amorphous dispersions of encorafenib, together with one or more surfactants and polymers, and to methods of using such solid forms and pharmaceutical compositions in the treatment of proliferative diseases such as cancer.

IPC Classes  ?

• A61K 9/14 - Particulate form, e.g. powders
• A61K 9/20 - Pills, lozenges or tablets
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Abstract

Disclosed herein are methods for treating cancer comprising administering to a subject Compound A, or a pharmaceutically acceptable salt thereof, in combination with a selective CDK7 inhibitor.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents

Abstract

Provided herein are methods of treatment of cancers, specifically multiple myelomas, with anti-fragment crystallizable receptor-like 5 (FcRH5)/anti-cluster of differentiation 3 (CD3) bispecific antibodies in combination with anti-B cell maturation factor (BCMA)/anti-CD3 bispecific antibodies.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• A61P 35/02 - Antineoplastic agents specific for leukemia
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The invention relates to RNA molecules encoding an E. coli fimbrial H antigen (FimH). The present disclosure further relates to compositions comprising the RNA molecules formulated in a lipid nanoparticle (RNA-LNP). The present disclosure further relates to the use of the RNA 5 molecules, RNA-LNPs and compositions for the prevention of E. coli infection, including urinary tract infection.

IPC Classes  ?

• C12N 15/67 - General methods for enhancing the expression
• C07K 14/245 - Escherichia (G)
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides

Abstract

The present disclosure is directed to solid forms of N-(Methoxycarbonyl)-3-methyl-L- valyl-(4R)-N-{(1S)-1-cyano-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl}-4-(trifluoromethyl)-L- prolinamide, I, such as anhydrous forms thereof, an amorphous form thereof, a cyclopentyl methyl ether solvate thereof, an isopropyl acetate solvate thereof, and an 5 ethyl acetate solvate thereof formula (I) and to pharmaceutical compositions comprising the solid forms and methods of treatment employing the solid forms.

IPC Classes  ?

• C07D 207/24 - Oxygen or sulfur atoms
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61P 31/14 - Antivirals for RNA viruses
• A61K 31/401 - ProlineDerivatives thereof, e.g. captopril

Abstract

The present disclosure is directed to processes for preparing N-(Methoxycarbonyl)-3- methyl-L-valyl-(4R)-N-{(1S)-1-cyano-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl}-4- (trifluoromethyl)-L-prolinamide, I, and forms thereof such as the Form I polymorph thereof, a cyclopentyl methyl ether solvate thereof, the isopropyl acetate solvate thereof, the ethyl acetate solvate thereof and a mixture of the Form 1 polymorph thereof and microcrystalline cellulose (I) and to compositions comprising the solid forms and to intermediates used to prepare Compound I.

IPC Classes  ?

• C07D 207/24 - Oxygen or sulfur atoms
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 207/06 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
• A61P 31/14 - Antivirals for RNA viruses
• A61K 31/401 - ProlineDerivatives thereof, e.g. captopril

Abstract

The invention relates to dosing regimens for the treatment of RSV infection comprising administering to a pediatric subject in need thereof a daily dose of a sisunatovir as a single agent or in combination with other RSV therapies.

IPC Classes  ?

• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The disclosure provides a method of treating cancer comprising administering to a subject in need thereof with a therapeutically effective amount of PF-07220060. The disclosure also provides a method of treating cancer comprising administering to a subject in need thereof with a therapeutically effective amount of PF-07220060 and an endocrine therapy agent.

IPC Classes  ?

• A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
• A61K 31/5685 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone having an oxo group in position 17, e.g. androsterone
• A61P 35/00 - Antineoplastic agents

Abstract

Disclosed herein are methods for treating cancer comprising administering to a subject Compound A, or a pharmaceutically acceptable salt thereof, in combination with a selective CDK4 inhibitor.

IPC Classes  ?

• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents

Abstract

The present disclosure provides methods and compositions for determining the risk of a patient being non-responsive to a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody and methods and compositions for treating inflammatory bowel disease (IBD) with a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The present disclosure relates to engineered RNA polymerase polypeptides and compositions thereof, as well as polynucleotides encoding the engineered RNA polymerase polypeptides. The present disclosure also provides methods of using the engineered RNA polymerase polypeptides or compositions thereof for producing RNA.

IPC Classes  ?

• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides

Abstract

The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), kits comprising said immunogenic compositions and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.

IPC Classes  ?

• A61K 39/09 - Streptococcus
• A61P 31/04 - Antibacterial agents

Abstract

In an embodiment, there is provided a varenicline formulation consisting essentially of about 0.85% varenicline tartrate and greater than 1.75% to about 3.0% propyl gallate, wherein the formulation maintains a level of N-nitrosovarenicline (NNV) impurity over the shelf-life of the formulation of not more than 18.5 ppm (37 ng/day) of acceptable daily intake (ADI). In another embodiment, there is provided a varenicline formulation comprising a tablet core comprising about 0.85% varenicline tartrate, about 60.50% microcrystalline cellulose, about 33.33% dibasic calcium phosphate anhydrous, about 2.00% croscarmellose sodium, about 2.57% propyl gallate, and about 0.75% magnesium stearate; and a film coating.

IPC Classes  ?

• A61K 9/20 - Pills, lozenges or tablets
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• A61P 25/34 - Tobacco-abuse

Abstract

Cells having improved growth and related cell cultures are provided. In some aspects, cells provided herein have increased expression of thioredoxin interacting protein (TXNIP).

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells

Abstract

The invention is directed to Anti-LILRB1 and anti-LILRB2 bispecific antibodies, anti-LILRB1 antibodies, and anti-LILRB2 antibodies, their uses and pharmaceutical compositions thereof.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents

Abstract

The invention relates to compounds of Formula (I)-(III) and pharmaceutically acceptable salts thereof; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds the present invention may be useful in the treatment, prevention, suppression and amelioration diseases, disorders, and conditions such as cancers.

IPC Classes  ?

• C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
• A61P 35/00 - Antineoplastic agents
• A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine

Abstract

Provided herein is a method of treating metastatic uveal melanoma (MUM) in a patient having a hepatic tumor and an essential absence of an extra-hepatic tumor with a PKC inhibitor and a c-MET inhibitor.

IPC Classes  ?

• A61P 35/04 - Antineoplastic agents specific for metastasis
• A61P 35/00 - Antineoplastic agents
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Abstract

The invention relates to compounds of Formula (I)-(III) and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their Intermediate; and to intermediates used in such processes. The compounds the present invention may be useful in the treatment, prevention, suppression and amelioration diseases, disorders and conditions such as cancers.

IPC Classes  ?

• C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
• A61P 35/00 - Antineoplastic agents
• A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine

Abstract

The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), kits comprising said immunogenic compositions and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.

IPC Classes  ?

• A61K 39/09 - Streptococcus
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61P 31/04 - Antibacterial agents

Abstract

Described herein are compounds of Formula I: and their pharmaceutically acceptable salts, wherein R1, R2, R3, L1, T1, T2, T3, T4, t1, and t2 are defined herein; their use as GIPR antagonists; pharmaceutical compositions containing such compounds and salts; and the use of such compounds and salts to treat or prevent, for example, obesity, weight gain, and/or T2DM.

IPC Classes  ?

• C07D 207/16 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• C07D 209/52 - Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim

Abstract

The invention relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1to R3 are as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of Formula (I) may inhibit the activity and/or expression of PLpro and may be useful in the treatment, prevention, suppression, and amelioration of viral infections characterized with PLpro activity and/or expression such as coronavirus infections.

IPC Classes  ?

• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 471/08 - Bridged systems
• C07D 498/08 - Bridged systems
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The invention relates to substituted indazole propionic acid derivatives of formula (I), pharmaceutically acceptable salts, tautomers, or pharmaceutically acceptable salts of the tautomers thereof that can activate adenosine 5'-monophosphate- activated protein kinase (AMPK). The invention further relates to pharmaceutical compositions comprising AMPK-activating substituted indazole propionic acid derivatives of formula (I), pharmaceutically acceptable salts, tautomers, or pharmaceutically acceptable salts of the tautomers thereof and at least one pharmaceutically acceptable excipient, and methods of treating a condition comprising administering AMPK-activating substituted indazole propionic acid derivatives of formula (I), pharmaceutically acceptable salts, tautomers, or pharmaceutically acceptable salts of the tautomers thereof.

IPC Classes  ?

• C07D 231/56 - BenzopyrazolesHydrogenated benzopyrazoles
• C07D 403/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
• C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 409/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
• C07D 417/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
• C07D 471/04 - Ortho-condensed systems
• A61P 37/00 - Drugs for immunological or allergic disorders
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61K 31/416 - 1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole

Abstract

The invention relates to compounds of Formula (I)-(III) and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds the present invention may be useful in the treatment, prevention, suppression and amelioration diseases, disorders and conditions such as cancers.

IPC Classes  ?

• C07D 498/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
• A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
• A61P 35/00 - Antineoplastic agents

Abstract

The invention relates to a method of forming multi-specific antibodies from first and second homodimer antibodies comprising the steps of: - providing at least one solution including the homodimer antibodies; - loading said at least one solution onto an adsorbent chromatography medium, whereby the homodimer antibodies bind to the medium; - contacting the bound antibodies with a reductant; and - eluting the bound antibodies with an elution buffer thereby obtaining an eluate pool. The method further comprises, after the step of contacting the bound antibodies with a reductant, a step of contacting the bound or eluted antibodies with an oxidant, whereby multi-specific antibodies are formed from first and second homodimer antibodies. The invention is also directed to a pharmaceutical product including multi-specific antibodies obtained by such a method.

IPC Classes  ?

• C07K 16/06 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies from serum

Abstract

The disclosure relates to a method for activating a medical testing device via near-field communication. The method can include verifying a digitally signed message received from a user device using a public key in a medical testing device. The medical testing device can be activated after the verification of the digitally signed message.

IPC Classes  ?

• G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
• G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
• H04L 9/32 - Arrangements for secret or secure communicationsNetwork security protocols including means for verifying the identity or authority of a user of the system
• H04L 9/40 - Network security protocols
• H04W 4/80 - Services using short range communication, e.g. near-field communication [NFC], radio-frequency identification [RFID] or low energy communication

Abstract

This invention relates to a method of selecting a subject having a cancer for treatment, comprising: i) determining a KAT6A level from a biological sample of the cancer from the subject; ii) selecting the subject for treatment and iii) administering to the selected subject an amount of with one of: a) a lysine acetyltransferase 6A (KAT6A) inhibitor; b) a lysine acetyltransferase 6A (KAT6A) inhibitor and a cyclin-dependent kinase 4 (CDK4) inhibitor; c) a lysine acetyltransferase 6A (KAT6A) inhibitor and an antiestrogen; and d) a lysine acetyltransferase 6A (KAT6A) inhibitor, a cyclin-dependent kinase 4 (CDK4) inhibitor, and an antiestrogen, based on the KAT6A level, wherein the KAT6A level is determined to be high.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• A61K 31/42 - Oxazoles
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Abstract

This invention relates to a method of selecting a subject having a cancer for treatment, comprising: i) determining a KAT6A level from a biological sample of the cancer from the subject; ii) selecting the subject for treatment with a cyclin-dependent kinase 4 (CDK4) inhibitor as a single agent or in combination with an antiestrogen, based on the KAT6A level, wherein the KAT6A level is determined to be low, and methods of treatment thereof. It is shown that lower than median KAT6A mRNA levels in metastatic tumor samples of patients with breast cancer qualify as a predictive biomarker for the response to a combination therapy with palbociclib and fulvestrant.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Abstract

S. pneumoniaeS. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.

IPC Classes  ?

• A61K 39/09 - Streptococcus
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61P 31/04 - Antibacterial agents

Abstract

The present disclosure provides methods and compositions for modulating the innate immunity to exogenous ribonucleic acid (RNA) when administered to a subject in need thereof. More particularly, the disclosure provides compositions comprising RNA encoding at least one antigen or therapeutic protein, and at least one compound that modulates the innate immunity to such RNA when administered to a subject in need thereof. The disclosure further provides methods of using such compounds to modulate the innate immunity of such compositions.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07D 487/04 - Ortho-condensed systems
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses

Abstract

Apparatuses and methods are provided for reducing fluidization of bulk material during dynamic freeze drying. Fluidization is reduced by improving the mixing behavior of the bulk material to increase inter- particulate bulk material porosity during lyophilization processes, which reduces pressure build-up in the bulk material. A new and innovative drum (100) for rotary freeze drying is provided that includes one or more baffles (500) constructed and arranged to form slits through which bulk material can pass as the drum (100) rotates to generate sheets of the bulk material. At least one of the baffles (500) may be disposed in a curved shape, such as a helical shape, along the interior surface of the drum (100). The curved shape directs the bulk material to one of the front and rear end of the drum (100) as the drum (100) rotates.

IPC Classes  ?

• F26B 5/06 - Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum the process involving freezing
• F26B 25/16 - Chambers, containers, receptacles of simple construction mainly closed, e.g. drum

Abstract

The present disclosure includes systems and methods for producing freeze-dried particles, such as in a continuous lyophilization process. In some aspects, the system (100) can include a spray freezing vessel (104) configured to freeze liquid droplets to form bulk material, one or more pre-conditioning vessels (108a-108c) configured to receive bulk material from the spray freezing vessel (104), and a freeze drying vessel (112) configured to receive the bulk material from the pre-conditioning vessel(s) (108a-108c) and to freeze-dry the bulk material therein. Each of the pre-conditioning vessel(s) (108a-108c) can be coupled to a vacuum source (156) and include a container, such as a rotary drum (132), controllable to move while bulk material is in the pre-conditioning vessel (108a-108c).

IPC Classes  ?

• F26B 5/06 - Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum the process involving freezing

Abstract

The present disclosure includes systems and methods for annealing bulk material in a dynamic bulk freeze drying process. In some aspects, the methods can include receiving frozen bulk material in a container (120) and annealing the frozen bulk material. In some configurations, the annealing can include heating a surface of the container (120) to a first temperature that is greater than or equal a glass transition temperature of the frozen bulk material and operating the container (120) to move.

IPC Classes  ?

• F26B 5/06 - Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum the process involving freezing
• F26B 25/16 - Chambers, containers, receptacles of simple construction mainly closed, e.g. drum

Abstract

A system, method, and anti-electrostatic device (110) are provided for reducing the build-up of electrostatic force during dynamic bulk freeze drying. The reduction of the amount of electrostatic force reduces the formation of static bulk material layers that do not participate in the overall bulk material movement and drying process, resulting in improved product yield, homogeneity, and quality. The provided anti-electrostatic device (110) is vacuum tight for dynamic bulk freeze drying operations at low vacuum pressure conditions. The anti-electrostatic device (110) is also suitable for manufacturing requirements like cleaning in place (CIP) and steam sterilization (SIP) for aseptic operation.

IPC Classes  ?

• F26B 5/06 - Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum the process involving freezing
• H01T 19/04 - Devices providing for corona discharge having pointed electrodes
• H05F 3/04 - Carrying-off electrostatic charges by means of spark gaps or other discharge devices

Abstract

The invention relates to an injection device comprising a housing (3), a needle guard (20), an injection drive mechanism for driving a plunger within a medicament container (5) and thus expelling the medicament, the drive mechanism including o a plunger rod (31) biased by an injection spring (34); o a retaining member (33) for initially retaining the plunger rod (31) in its proximal position; and o a trigger member (35), mounted onto the retaining member (33). The retraction of the needle guard (20) causes the trigger member (35) to move proximally and thus causes the release of the plunger rod (31). The device (1) further comprises a lockout mechanism for preventing retraction of the needle guard (20) after use of the device, the lockout mechanism comprising a cam system provided on the trigger member (35) and the retaining member (33), that prevents the trigger member from rotating as the needle guard (20) is retracted and that is caused to rotate into a blocking position when the needle guard (20) is returned to its extended position after firing of the device.

IPC Classes  ?

• A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
• A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
• A61M 5/315 - PistonsPiston-rodsGuiding, blocking or restricting the movement of the rodAppliances on the rod for facilitating dosing

Abstract

The invention relates to an injection device comprising a housing (3), a needle guard (20), an injection drive mechanism for driving a plunger within the container (5) and including o a plunger rod (31); o an injection spring (34) for biasing the plunger rod; o a retaining member (33), the retaining member and the plunger rod having corresponding latching features for retaining the plunger rod in its proximal position against the action of the injection spring, in an initial state of the injection device; and o a trigger member (35) for preventing the release of the latching features in the initial state of the device, the trigger member being axially displaceable by the needle guard (20) for releasing the latching features. The trigger member (35) and the housing (3) comprise corresponding locking features (79, 139) in mutual releasable engagement for maintaining the trigger member (35) in its blocking position, and wherein said locking features are designed to be released by the needle guard (20) when moving to its retracted position.

IPC Classes  ?

• A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
• A61M 5/315 - PistonsPiston-rodsGuiding, blocking or restricting the movement of the rodAppliances on the rod for facilitating dosing
• A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles

Abstract

The invention relates to a syringe comprising a barrel having an interior surface, a plunger slidingly mounted within the barrel and a lubricious silicone-based coating applied to one of the frictional engagement surfaces defined by a barrel interior surface and an outer surface of the plunger. The coating is applied by a dipping method including at least two dipping cycles. The invention also relates to a method of applying a lubricious silicone-based coating and to a plunger thus coated.

IPC Classes  ?

• A61M 5/31 - Syringes Details
• A61M 5/315 - PistonsPiston-rodsGuiding, blocking or restricting the movement of the rodAppliances on the rod for facilitating dosing

Abstract

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more influenza antigens, such as hemagglutinin antigens.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses

Abstract

Self-amplifying RNA (saRNA) molecules encoding an influenza virus antigen and methods of use thereof are disclosed herein.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C12N 15/86 - Viral vectors

Abstract

The present invention relates to new conjugated capsular saccharide antigens (glycoconjugates), immunogenic compositions comprising said glycoconjugates and uses thereof.

IPC Classes  ?

• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61K 39/09 - Streptococcus
• A61K 39/02 - Bacterial antigens
• A61P 31/04 - Antibacterial agents

Abstract

Compounds are provided having the following structure Formula (I) or a pharmaceutically acceptable salt, N-oxide, tautomer or stereoisomer thereof, wherein G1, G2, G3, L1, L2, R1, R2, R3, W and Y are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a nucleic acid, compositions comprising the compounds and methods for their use and preparation are also provided.

IPC Classes  ?

• C07C 229/08 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
• A61K 47/00 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient

Abstract

The present disclosure provides for methods of inducing an immune response against varicella zoster virus (VZV) in a human subject. The methods provided herein comprise administering immunogenic compositions (e.g., vaccines) comprising RNA molecules formulated in a lipid nanoparticle to a human subject. The present disclosure further relates to the use of immunogenic compositions for preventing or treating of herpes zoster in a human subject.

IPC Classes  ?

• A61K 39/12 - Viral antigens

Abstract

Described herein are compositions and methods for stabilizing RNA molecules. Also described herein a 5' and 3' untranslated regions for use in therapeutic and vaccine applications.

IPC Classes  ?

• C12N 15/67 - General methods for enhancing the expression
• C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Abstract

The present disclosure relates to hMPV F, PIV3 F and PIV1 F protein mutants, nucleic acids or vectors encoding a hMPV F, PIV3 F and PIV1 F protein mutant, compositions comprising a hMPV F, PIV3 F and PIV1 F protein mutant or nucleic acid, and uses of the hMPV F, PIV3 F and PIV1 F protein mutants, nucleic acids or vectors, and compositions.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61K 39/155 - Paramyxoviridae, e.g. parainfluenza virus
• A61P 31/14 - Antivirals for RNA viruses
• C07K 14/08 - RNA viruses
• C07K 14/115 - Paramyxoviridae, e.g. parainfluenza virus

Abstract

The present disclosure relates to the field of Type 1 diabetes. More specifically, the present disclosure provides pharmaceutical compositions and methods for treating and/or preventing Type 1 diabetes. In certain embodiments, pharmaceutical compositions and methods comprise administering to a patient or subject a therapeutically effective amount of a JAK1 inhibitor, for 5 example, abrocitinib. In certain embodiments, pharmaceutical compositions and methods comprise administering to a patient or subject a therapeutically effective amount of a JAK3/TEC inhibitor, for example ritlecitinib.

IPC Classes  ?

• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems

Abstract

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of ribonucleic acid immunogenic compositions and/or vaccines comprising polynucleotide molecules preferably encoding one or more influenza antigens, such as hemagglutinin antigens, wherein the composition is frozen or lyophilized.

IPC Classes  ?

• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 31/70 - CarbohydratesSugarsDerivatives thereof
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 49/00 - Preparations for testing in vivo

Abstract

The present disclosure relates to compositions comprising RNA molecules encoding an antigen derived from influenza, wherein the RNA may be formulated in a lipid nanoparticle (LNP), and wherein the composition further includes a polypeptide antigen derived from respiratory syncytial virus (RSV) and/or RNA molecules encoding an antigen derived from RSV, wherein the RSV RNA may be may be formulated in an LNP. The present disclosure further relates to the use of the RNA molecules, RNA-LNPs and compositions for the prevention of influenza and RSV infection-induced illness.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/87 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Abstract

This invention relates to talazoparib, or a pharmaceutically acceptable salt thereof, in combination with enzalutamide, or a pharmaceutically acceptable salt thereof, for the treatment of homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer and methods of increasing survival thereof.

IPC Classes  ?

• A61K 31/4166 - 1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
• A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to immunogenic compositions that comprise a Clostridioides difficile toxoid A and/or a C. difficile toxoid B, and an adjuvant, and methods of use thereof. The present invention further relate to a methods for eliciting an enhanced immune response in a human against a C. difficile infection. The methods include administering to the human an effective dose of an immunogenic composition, which includes a C. difficile toxoid and an adjuvant, wherein the composition is administered two times.

IPC Classes  ?

• A61K 39/08 - Clostridium, e.g. Clostridium tetani
• A61P 31/04 - Antibacterial agents

Abstract

Described herein are 3-fluoro-4-hydroxybenzamide-containing inhibitors and/or degraders, and pharmaceutical compositions containing 3-fluoro-hydroxybenzamide-containing inhibitors and/or degraders. In some embodiments, the 3-fluoro-4-hydroxybenzamide- containing compounds of the disclosure can be used to treat a condition, for example, nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Formula (II).

IPC Classes  ?

• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 35/00 - Antineoplastic agents
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 498/10 - Spiro-condensed systems
• C07D 487/04 - Ortho-condensed systems
• C07D 471/04 - Ortho-condensed systems
• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
• A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
• A61K 31/5386 - 1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone

Abstract

Dosing regimens and methods for administering combination therapies combining a CD47 blocking agent and an anti-BCMA / anti-CD3 bispecific antibody are provided. The dosing regimens and methods may further include additional therapeutic agents.

IPC Classes  ?

• A61P 35/02 - Antineoplastic agents specific for leukemia
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The invention relates to compounds of Formula (I) (I) and pharmaceutically acceptable salts thereof as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of Formula (I) may inhibit the activity of papain-like protease (PLpro) and may be useful in the treatment of viral infections, in particular viral infections associated with with PLpro activity and/or expression such as coronaviruses infections.

IPC Classes  ?

• C07D 207/416 - 2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
• C07D 231/12 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• C07D 249/06 - 1,2,3-TriazolesHydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 409/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 471/08 - Bridged systems
• C07D 471/10 - Spiro-condensed systems
• C07D 487/04 - Ortho-condensed systems
• C07D 487/08 - Bridged systems
• C07D 495/04 - Ortho-condensed systems
• A61K 31/4192 - 1,2,3-Triazoles
• A61P 31/12 - Antivirals

Abstract

The invention relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of Formula (I) may inhibit the activity of papain-like protease (PLpro) and may be useful in the treatment of viral infections, in particular viral infections associated with with PLpro activity and/or expression such as coronaviruses infections.

IPC Classes  ?

• C07D 231/12 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 403/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 409/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
• C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 417/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 471/08 - Bridged systems
• C07D 487/04 - Ortho-condensed systems
• A61P 31/12 - Antivirals
• A61K 31/4164 - 1,3-Diazoles

Abstract

The disclosure provides, among other embodiments, AAV rep genes and rep/cap transcription units modified to reduce the amount of AAV Rep protein relative to AAV capsid protein expressed in cells, thereby improving the yield of recombinant AAV vectors produced in such cells, for example, using the triple transfection technique or other methods.

IPC Classes  ?

• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C12N 15/86 - Viral vectors

Abstract

Dosing regimens and methods for administering combination therapies combining a CD47 blocking agent and an anti-CD20 / anti-CD3 bispecific antibody are provided. The dosing regimens and methods may further include additional therapeutic agents.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

Provided herein are Claudin 18.2 binding agents and chimeric antigen receptors (CARs) comprising a Claudin 18.2 binding molecule that specifically binds to Claudin 18.2; and immune cells comprising these Claudin 18.2-specific CARs, e.g., CAR-T cells. Also provided are methods of making and using Claudin 18.2-specific CARs and Claudin 18.2 binding agents, and immune cells comprising Claudin 18.2-specific CARs.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• A61P 35/04 - Antineoplastic agents specific for metastasis
• C07K 14/725 - T-cell receptors
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

Streptococcus pneumoniaeS. pneumoniaeS. pneumoniae serotype in a formulation designed to facilitate resuspension.

IPC Classes  ?

• A61K 9/08 - Solutions
• A61K 39/09 - Streptococcus
• A61K 47/02 - Inorganic compounds
• A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent

Abstract

123455 are as defined herein. The disclosure is also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds and methods of preparing the compounds.

IPC Classes  ?

• C07D 471/14 - Ortho-condensed systems
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems

Abstract

The invention relates to a method for treating cancer in a subject receiving a substrate of P-glycoprotein comprising administering Compound A having a structure of: or a pharmaceutically acceptable salt thereof, to the subject and monitoring the subject for adverse reactions during treatment with Compound A, or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
• A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents

Abstract

StreptococcuspneumoniaeS. pneumoniaeS. pneumoniae serotype not found in Prevnar, Synflorix and/or Prevnar 13. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said novel immunogenic compositions.

IPC Classes  ?

• A61K 39/09 - Streptococcus
• A61P 31/04 - Antibacterial agents
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent

Abstract

The present invention relates to methods for preparing conjugated capsular saccharide antigens (glycoconjugates), immunogenic compositions comprising said glycoconjugates and uses thereof.

IPC Classes  ?

• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61K 39/09 - Streptococcus

Abstract

1234566, W, X, Y, and q are as defined herein, to pharmaceutical compositions comprising such compounds and salts; to processes for their preparation; to intermediates used in such process; and to methods of using such compounds, salts and compositions for the treatment of immunosuppression-associated disorders such as chronic viral infections and cancer.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61P 35/00 - Antineoplastic agents

Abstract

Technology is disclosed for a method for performing crystallization, where the method may include utilizing a software algorithm, and perform a crystallization process using the software algorithm.

IPC Classes  ?

• B01D 9/00 - Crystallisation
• G06N 20/00 - Machine learning
• G16C 20/10 - Analysis or design of chemical reactions, syntheses or processes
• G16C 20/70 - Machine learning, data mining or chemometrics

Abstract

The present invention relates to prodrugs of compounds that contain vulnerable amines (e,g, secondary, tertiary and quaternary amines), and methods for their manufacture.

IPC Classes  ?

• A61P 25/34 - Tobacco-abuse
• A61K 31/4965 - Non-condensed pyrazines
• C07D 471/08 - Bridged systems
• C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or

Abstract

Compounds are provided having the following structure: (I) or a pharmaceutically acceptable salt, N-oxide, tautomer or stereoisomer thereof, wherein R1, G1, W and m, n, o and p are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a nucleic acid, compositions comprising the compounds and methods for their use and preparation are also provided.

IPC Classes  ?

• C07D 209/54 - Spiro-condensed
• C07D 221/20 - Spiro-condensed ring systems
• C07D 471/10 - Spiro-condensed systems

Abstract

The present disclosure relates to compositions comprising RNA molecules encoding an antigen derived from influenza, wherein the RNA is formulated in a lipid nanoparticle (LNP), and wherein the composition further includes a polypeptide antigen derived from respiratory syncytial virus (RSV). The composition may be used for the prevention of illnesses induced by influenza and RSV infection.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/87 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Abstract

The present disclosure relates to RNA molecules encoding a respiratory syncytial virus (RSV). The present disclosure further relates to compositions comprising the RNA molecules formulated in a lipid nanoparticle (RNA-LNP). The present disclosure further relates to the use of the RNA molecules, RNA-LNPs and compositions for the treatment and/or prevention of RSV infection-induced acute respiratory tract illness, including pneumonia and bronchitis.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/87 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Abstract

Described herein are compounds of Formula I, wherein the variables are defined herein, their use as activators from AMPK, pharmaceutical compositions containing such compounds and their use to treat, for example, heart failure or peripheral vascular disease.

IPC Classes  ?

• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 471/04 - Ortho-condensed systems
• C07D 498/08 - Bridged systems
• C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/5386 - 1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems

Abstract

The invention relates to vaccination of human subjects, in particular elderly, against pneumoccocal and COVID-19 infections.

IPC Classes  ?

• A61K 39/09 - Streptococcus
• A61K 39/116 - Polyvalent bacterial antigens
• A61K 39/12 - Viral antigens
• A61K 39/295 - Polyvalent viral antigensMixtures of viral and bacterial antigens
• A61K 39/385 - Haptens or antigens, bound to carriers
• A61P 31/04 - Antibacterial agents
• A61P 31/14 - Antivirals for RNA viruses
• A61K 39/00 - Medicinal preparations containing antigens or antibodies